In 2016, the revision of the WHO classification of CNS tumors has highlighted the importance of the IDH1 or IDH2 mutation and co-deletion of chromosomal arms 1p and 19q for the diagnosis of gliomas [5]. This evidence concerns the gene IDH1 and central nervous system cancer.